| (D-Trp32)-Neuropeptide Y (porcine) |
|
|
|
|
|
| (Leu31,Pro34)-Peptide YY (human) |
|
|
|
|
|
| (Leu31,Pro34)-Peptide YY (human) TFA |
|
|
|
|
98.63% |
| (Pro34)-Peptide YY (human) |
|
|
|
|
|
| (R)-JNJ-31020028 |
|
|
|
|
|
| (S)-VU0637120 |
|
|
|
|
99.5% |
| 26Rfa, Hypothalamic Peptide, human |
|
|
|
|
|
| [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide |
|
|
|
|
99.25% |
| [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic polypeptide TFA |
|
|
|
|
|
| [D-Arg25]-Neuropeptide Y (human) |
|
|
|
|
|
| [D-His26]-Neuropeptide Y, human, rat |
|
|
|
|
|
| [D-Trp34]-Neuropeptide Y |
|
|
|
|
99.70% |
| [D-Trp34]-Neuropeptide Y TFA |
|
|
|
|
|
| [D-Tyr27,36, D-Thr32]-Neuropeptide Y (27-36), rat |
|
|
|
|
|
| [Leu31,Pro34]-Neuropeptide Y (human,rat) |
|
|
|
|
|
| [Leu31,Pro34]-Neuropeptide Y (porcine) |
|
|
|
|
99.66% |
| [Leu31,Pro34]-Neuropeptide Y(human,rat,mouse) TFA |
|
|
|
|
98.00% |
| [Pro34]Neuropeptide Y, porcine |
|
|
|
|
|
| Ala5-Galanin (2-11) |
|
|
|
|
|
| Allo-aca |
|
|
|
|
99.82% |
| Allo-aca TFA |
|
|
|
|
|
| Anti-Galanin Antibody |
|
|
|
|
|
| AR-M1896 |
|
|
|
|
|
| BIBO3304 |
|
|
|
|
99.96% |
| BIBO3304 (Standard) |
|
|
|
|
|
| BIBO3304 diTFA |
|
|
|
|
|
| BIBO3304 free base |
|
|
|
|
|
| BIBP3226 |
|
|
|
|
98.78% |
| BIBP3226 TFA |
|
|
|
|
99.92% |
| BIIE-0246 |
|
|
|
|
99.10% |
| BIIE-0246 dihydrochloride |
|
|
|
|
|
| BIIE-0246 hydrochloride |
|
|
|
|
99.33% |
| BMS-193885 |
|
|
|
|
99.91% |
| BMS-193885 L-Lactic acid |
|
|
|
|
|
| BVD 10 |
|
|
|
|
|
| BWX 46 |
|
|
|
|
|
| CART (1-39), Human |
|
|
|
|
99.79% |
| CART (55-76), rat |
|
|
|
|
|
| CART(55-102)(human) |
|
|
|
|
99.41% |
| CART(55-102)(human) TFA |
|
|
|
|
|
| CART(55-102)(rat) |
|
|
|
|
99.53% |
| CART(55-102)(rat) TFA |
|
|
|
|
|
| CGP71683 |
|
|
|
|
|
| CGP71683 hydrochloride |
|
|
|
|
99.44% |
| CYM 9484 |
|
|
|
|
98.68% |
| CYM 9484 (Standard) |
|
|
|
|
|
| CYM2503 |
|
|
|
|
96.01% |
| FR252384 |
|
|
|
|
|
| Galanin (1-13)-Neuropeptide Y (25-36) amide |
|
|
|
|
|
| Galanin (1-13)-spantide I |
|
|
|
|
|
| Galanin (1-16), mouse, porcine, rat |
|
|
|
|
|
| Galanin (1-16), mouse, porcine, rat TFA |
|
|
|
|
99.92% |
| Galanin (1-19), human |
|
|
|
|
99.25% |
| Galanin (1-29)(rat, mouse) |
|
|
|
|
|
| Galanin (1-29)(rat, mouse) TFA |
|
|
|
|
99.70% |
| Galanin (1-30), human |
|
|
|
|
99.91% |
| Galanin (2-29) (rat) |
|
|
|
|
|
| Galanin (swine) |
|
|
|
|
98.99% |
| Galanin (swine) TFA |
|
|
|
|
|
| Galanin Receptor Ligand M35 |
|
|
|
|
96.52% |
| Galanin Receptor Ligand M35 TFA |
|
|
|
|
|
| Galanin-Like Peptide (human) |
|
|
|
|
|
| Galanin-Like Peptide (porcine) |
|
|
|
|
|
| Galanin-Like Peptide (rat) |
|
|
|
|
|
| Galantide |
|
|
|
|
|
| Galantide TFA |
|
|
|
|
98.77% |
| Galnon |
|
|
|
|
|
| Galnon TFA |
|
|
|
|
98.88% |
| GEP12 |
|
|
|
|
|
| GEP44 |
|
|
|
|
|
| GR231118 |
|
|
|
|
|
| GR231118 TFA |
|
|
|
|
|
| GW438014A |
|
|
|
|
99.98% |
| HT-2157 |
|
|
|
|
98.0% |
| human GALP (3-32) |
|
|
|
|
|
| J-115814 |
|
|
|
|
|
| JNJ-31020028 |
|
|
|
|
98.07% |
| JNJ-5207787 |
|
|
|
|
98.00% |
| L 152804 |
|
|
|
|
99.89% |
| L 152804 (Standard) |
|
|
|
|
|
| Levitide |
|
|
|
|
|
| Lu AA33810 |
|
|
|
|
98.3% |
| M1145 |
|
|
|
|
99.96% |
| M1145 TFA |
|
|
|
|
|
| M40 |
|
|
|
|
|
| M40 TFA |
|
|
|
|
98.33% |
| M617 |
|
|
|
|
99.54% |
| M617 TFA |
|
|
|
|
99.38% |
| M871 |
|
|
|
|
99.98% |
| Mibavademab |
|
|
|
|
≥99.0% |
| MK-0557 |
|
|
|
|
99.80% |
| ML154 |
|
|
|
|
99.59% |
| N-Acetyl [Leu28, Leu31] neuropeptide Y (24–36) |
|
|
|
|
98.03% |
| Neuropeptide AF (cattle) |
|
|
|
|
|
| Neuropeptide S (mouse) |
|
|
|
|
98.83% |
| Neuropeptide S(Rat) |
|
|
|
|
99.57% |
| Neuropeptide S(Rat) TFA |
|
|
|
|
|
| Neuropeptide SF(mouse,rat) |
|
|
|
|
|
| Neuropeptide SF(mouse,rat) TFA |
|
|
|
|
|
| Neuropeptide Y (1-24) (human) |
|
|
|
|
|
| Neuropeptide Y (13-36), amide, human |
|
|
|
|
98.77% |
| Neuropeptide Y (13-36), porcine |
|
|
|
|
99.31% |
| Neuropeptide Y (18-36) (porcine) |
|
|
|
|
98.76% |
| Neuropeptide Y (2-36) (porcine) |
|
|
|
|
|
| Neuropeptide Y (22-36) |
|
|
|
|
|
| Neuropeptide Y (3-36) (human, rat) |
|
|
|
|
96.94% |
| Neuropeptide Y (3-36) (porcine) |
|
|
|
|
|
| Neuropeptide Y (human) free acid |
|
|
|
|
|
| Neuropeptide Y (human,rat,mouse) |
|
|
|
|
99.94% |
| Neuropeptide Y (human,rat,mouse) TFA |
|
|
|
|
99.28% |
| Neuropeptide Y (scrambled) |
|
|
|
|
|
| Neuropeptide Y Y1 receptor antagonist 1 |
|
|
|
|
|
| Neuropeptide Y(29-64) |
|
|
|
|
99.85% |
| Neuropeptide Y5 receptor ligand-1 |
|
|
|
|
98.0% |
| Nisotirostide |
|
|
|
|
99.45% |
| NNC0165-1273 |
|
|
|
|
|
| NNC0165-1273 TFA |
|
|
|
|
|
| NPY Y2 antagonist 1 |
|
|
|
|
99.60% |
| NPY Y2 antagonist 2 |
|
|
|
|
|
| NPY-5 receptor antagonist-1 |
|
|
|
|
99.86% |
| NPY1R Human Pre-designed siRNA Set A |
|
|
|
|
|
| Npy1r Mouse Pre-designed siRNA Set A |
|
|
|
|
|
| Npy1r Rat Pre-designed siRNA Set A |
|
|
|
|
|
| NPY2R Human Pre-designed siRNA Set A |
|
|
|
|
|
| Npy2r Mouse Pre-designed siRNA Set A |
|
|
|
|
|
| NPY2R Rat Pre-designed siRNA Set A |
|
|
|
|
|
| NPY4R Human Pre-designed siRNA Set A |
|
|
|
|
|
| Npy4r Mouse Pre-designed siRNA Set A |
|
|
|
|
|
| Npy4r Rat Pre-designed siRNA Set A |
|
|
|
|
|
| Npy5r Mouse Pre-designed siRNA Set A |
|
|
|
|
|
| Npy5r Rat Pre-designed siRNA Set A |
|
|
|
|
|
| NPY5RA-972 |
|
|
|
|
98.99% |
| NPY5RA-972 (Standard) |
|
|
|
|
|
| NTNCB hydrochloride |
|
|
|
|
98.36% |
| OB3 |
|
|
|
|
|
| Pancreatic polypeptide |
|
|
|
|
99.65% |
| Pancreatic polypeptide TFA |
|
|
|
|
99.47% |
| Pancreatic Polypeptide, bovine |
|
|
|
|
|
| Pancreatic Polypeptide, human |
|
|
|
|
99.39% |
| Pancreatic Polypeptide, rat |
|
|
|
|
|
| PD 160170 |
|
|
|
|
|
| Peptide YY (13-36) (canine, mouse, porcine, rat) |
|
|
|
|
99.22% |
| Peptide YY (pig) |
|
|
|
|
|
| Peptide YY (PYY) (3-36), Human |
|
|
|
|
98.00% |
| Peptide YY (PYY) (3-36), porcine |
|
|
|
|
|
| Peptide YY (PYY) (3-36), porcine TFA |
|
|
|
|
99.97% |
| Peptide YY (PYY), human |
|
|
|
|
99.17% |
| R06039-636 |
|
|
|
|
|
| RF9 |
|
|
|
|
99.37% |
| RF9 (Standard) |
|
|
|
|
|
| RF9 hydrochloride |
|
|
|
|
99.91% |
| RFRP-1(human) |
|
|
|
|
99.00% |
| RFRP-1(human) TFA |
|
|
|
|
|
| RFRP-3(human) |
|
|
|
|
99.43% |
| RFRP-3(human) TFA |
|
|
|
|
|
| RTI-118 |
|
|
|
|
99.02% |
| S 25585 |
|
|
|
|
99.13% |
| S 25585 (Standard) |
|
|
|
|
|
| SCH 430765 |
|
|
|
|
|
| SF 11 |
|
|
|
|
98.76% |
| SF-22 |
|
|
|
|
99.49% |
| Spexin |
|
|
|
|
99.12% |
| Spexin TFA |
|
|
|
|
|
| SR 142948A |
|
|
|
|
99.0% |
| tBPC |
|
|
|
|
98.41% |
| TC2 |
|
|
|
|
|
| TC4 |
|
|
|
|
|
| VU0506013 |
|
|
|
|
|
| Y1R probe-1 |
|
|
|
|
|
| Y4R agonist-1 |
|
|
|
|
|
| Y4R agonist-2 |
|
|
|
|
|
| Tiglic acid |
|
|
|
|
99.74% |
| Velneperit |
|
|
|
|
98.25% |